Fexofenadine HCl 60 mg/Pseudoephedrine HCl 120 mg Has a 60-Minute Onset of Action in the Treatment of Seasonal Allergic Rhinitis Symptoms, as Assessed in an Allergen Exposure Unit

Authors: Berkowitz, Robert B.; McCafferty, Frank; Lutz, Cheryl; Bazelmans, Donna; Godfrey, Penny; Meeves, Suzanne; Liao, Yuning; Georges, George

Source: Allergy and Asthma Proceedings, Volume 25, Number 5, September-October 2004 , pp. 335-343(9)

Publisher: OceanSide Publications, Inc

Buy & download fulltext article:

Price: $39.50 plus tax (Refund Policy)

Abstract:

Although antihistamine-decongestant combinations are frequently used for allergic rhinitis, published data about the onset of action of these combination agents are limited. This randomized, double-blind, placebo-controlled, parallel-group study investigated the onset of action, efficacy, and safety of fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg or placebo in patients with moderate-to-severe seasonal allergic rhinitis in an allergen exposure unit. Assessments included major symptom complex (MSC) score (sum of sneezing, itchy nose, runny nose, watery eyes, itchy eyes, itchy ears/throat, and stuffy nose), and total symptom complex (TSC) score (MSC symptoms plus nose blows, sniffles, post-nasal drip, and cough). Onset of action was defined as the first time that two consecutive, statistically significant absolute changes in MSC scores from baseline were achieved for study drug relative to placebo. The onset of action for the combination was 60 minutes (mean absolute MSC change from baseline: -6.9 ± 0.3 for the combination compared with -5.9 ± 0.3 for placebo from a baseline of 17.0 and 16.8, respectively; p < 0.05) for the modified intention-to-treat population (n = 48). Reductions in absolute MSC scores were significantly greater with the combination than placebo at all subsequent time points (p < 0.01). The combination resulted in significantly greater reductions compared with placebo for percent MSC, absolute TSC, and percent TSC scores at 60 minutes postdose (all p < 0.05) and throughout the study (all p < 0.05). The incidence of adverse events was 1.6 and 3.3% for the combination and placebo, respectively. In conclusion, fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg is effective in the treatment of patients with moderate-to-severe seasonal AR, with an onset of action of 60 minutes and a good safety profile.

Document Type: Research article

Publication date: 2004-09-01

More about this publication?

Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
Editorial Board
Information for Authors
Submit a Paper
Information for Advertisers
Reprint Requests
ingentaconnect is not responsible for the content or availability of external websites

Fexofenadine HCl 60 mg/Pseudoephedrine HCl 120 mg Has a 60-Minute Onset of Action in the Treatment of Seasonal Allergic Rhinitis Symptoms, as Assessed in an Allergen Exposure Unit

Buy & download fulltext article:

Tools

Key

Text size:

Useful pages